OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?	1303
Technology of deep brain stimulation: current status and future directions	358
Lifting the mask on neurological manifestations of COVID-19	318
Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies	279
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases	271
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities	257
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities	230
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	229
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	228
Applications of focused ultrasound in the brain: from thermoablation to drug delivery	220
Diagnosis and management of migraine in ten steps	205
Prodromal Parkinson disease subtypes — key to understanding heterogeneity	185
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease	173
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	171
Complement in neurological disorders and emerging complement-targeted therapeutics	165
Developing the ATX(N) classification for use across the Alzheimer disease continuum	151
Improving clinical trial outcomes in amyotrophic lateral sclerosis	149
Cycles in epilepsy	145
The effects of the COVID-19 pandemic on people with dementia	137
Neurological infection with SARS-CoV-2 — the story so far	132
GAD antibodies in neurological disorders — insights and challenges	131
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	130
The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology	120
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies	119
Advances in local therapy for glioblastoma — taking the fight to the tumour	115

Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours	111
The human connectome in Alzheimer disease — relationship to biomarkers and genetics	108
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	108
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility	108
Stroke in Africa: profile, progress, prospects and priorities	107
Treatment and management of cognitive dysfunction in patients with multiple sclerosis	104
Management of brain metastases according to molecular subtypes	101
Virtual reality in research and rehabilitation of gait and balance in Parkinson disease	101
Drug repositioning and repurposing for Alzheimer disease	99
Synaptic degeneration in Alzheimer disease	97
Circadian rhythms in neurodegenerative disorders	97
Spinal muscular atrophy — insights and challenges in the treatment era	93
CRISPR-based functional genomics for neurological disease	92
Metagenomics for neurological infections — expanding our imagination	90
MicroRNAs as regulators of brain function and targets for treatment of epilepsy	90
Status of peripheral sodium channel blockers for non-addictive pain treatment	86
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers	86
The inter-relationship between delirium and dementia: the importance of delirium prevention	84
Hypomyelinating leukodystrophies — unravelling myelin biology	84
The neuroanatomical–functional paradox in spinal cord injury	79
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease	74
Apparent changes in the epidemiology and severity of multiple sclerosis	74
The metabolic basis of epilepsy	73
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	67
Aducanumab and the FDA — where are we now?	67
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	66
Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration	66
Amyloid-β: a potential link between epilepsy and cognitive decline	64
Can we learn lessons from the FDA’s approval of aducanumab?	64
Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities	64
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials	62
White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies	62
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era	62
Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19	61
International consensus recommendations on the diagnostic work-up for malformations of cortical development	60
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	60
Neurobehavioural comorbidities of epilepsy: towards a network-based precision taxonomy	59
Human cerebral organoids — a new tool for clinical neurology research	59
Global epidemiology of migraine and its implications for public health and health policy	59
Impact of predictive, preventive and precision medicine strategies in epilepsy	59
Alzheimer disease in African American individuals: increased incidence or not enough data?	58
The multiple sclerosis prodrome	56
Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap	56
The role of glial cells in multiple sclerosis disease progression	55
Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature	54
Nodes of Ranvier during development and repair in the CNS	53
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	53
Sex and gender in neurodevelopmental conditions	52
The role of the gut microbiota in multiple sclerosis	49
Astrocytes in the initiation and progression of epilepsy	49

The B cell immunobiology that underlies CNS autoantibody-mediated diseases	49
Mind the gap: from neurons to networks to outcomes in multiple sclerosis	48
Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP	48
Changing demography and the challenge of dementia in India	47
Artificial intelligence for decision support in acute stroke — current roles and potential	46
Early-stage Alzheimer disease: getting trial-ready	46
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease	46
The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA	45
Cluster headache pathophysiology — insights from current and emerging treatments	45
MRI biomarkers in neuro-oncology	43
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	43
Autonomic manifestations of epilepsy: emerging pathways to sudden death?	42
Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease	39
Bruton tyrosine kinase inhibitors for multiple sclerosis	38
Nuclear pore complexes — a doorway to neural injury in neurodegeneration	37
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	37
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes	36
Genetics of common cerebral small vessel disease	35
Perinatal stroke: mapping and modulating developmental plasticity	35
Rapidly progressive dementias — aetiologies, diagnosis and management	33
Review and update of the concept of embolic stroke of undetermined source	32
Refining oxytocin therapy for autism: context is key	32
Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects	32
Drug-resistant epilepsy — time to target mechanisms	32
The neurovascular unit and systemic biology in stroke — implications for translation and treatment	32
Multifaceted microglia — key players in primary brain tumour heterogeneity	31
COVID-19 and management of neuroimmunological disorders	31
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	31
Applying genomic and transcriptomic advances to mitochondrial medicine	30
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain	30
hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible	30
Social determinants of health in multiple sclerosis	30
Emerging therapies to target CNS pathophysiology in multiple sclerosis	29
Lecanemab trial in AD brings hope but requires greater clarity	29
Vaccination and immunotherapies in neuroimmunological diseases	29
Positron emission tomography in multiple sclerosis — straight to the target	28
Prospective memory impairment in neurological disorders: implications and management	28
A global view of the genetic basis of Alzheimer disease	28
Inflammation in multiple sclerosis: consequences for remyelination and disease progression	26
From the prodromal stage of multiple sclerosis to disease prevention	26
Genetic testing in dementia — utility and clinical strategies	26
‘Concussion’ is not a true diagnosis	25
Global synergistic actions to improve brain health for human development	23
New insights into the neurological effects of COVID-19	22
Inequities in neurology amplified by the COVID-19 pandemic	21
Neurological telemedicine in the COVID-19 era	21
Closing the loop for patients with Parkinson disease: where are we?	21
Headache in people with epilepsy	21
Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal	21
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	21
Neuroprognostication: a conceptual framework	20
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions	19
Maximizing treatment efficacy through patient stratification in neuropathic pain trials	19
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	19
Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries	19
Neurogenetic disorders across the lifespan: from aberrant development to degeneration	19
Cognitive impairment and World Trade Centre-related exposures	18
Tau-targeting therapies for Alzheimer disease: current status and future directions	18
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges	18
Functional brain networks in the evaluation of patients with neurodegenerative disorders	18
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	18
Genetic generalized epilepsies in adults — challenging assumptions and dogmas	17
The childhood migraine syndrome	17
Cognitive impairment in people living with HIV: consensus recommendations for a new approach	17
Counting the neurological cost of COVID-19	17
SARS-CoV-2 detected in olfactory neurons	16
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	16
Adaptive and maladaptive myelination in health and disease	16
A cultural approach to dementia — insights from US Latino and other minoritized groups	16
Towards treating progressive multiple sclerosis	15
Recessive cerebellar and afferent ataxias — clinical challenges and future directions	14
The challenges of anti-tau therapeutics in Alzheimer disease	14
Why functional neurological disorder is not feigning or malingering	14
Isoform-dependent APOE secretion modulates neuroinflammation	13
Beyond recanalization — a call for action in acute stroke	13
Cell-based therapies for neurological disorders — the bioreactor hypothesis	13